technology-transfer-agreement

# Technology Transfer Agreement

Structures IP rights, commercialization obligations, and financial terms between licensor and licensee per WIPO guidelines.

## Prerequisites

Gather before drafting:

1. **Parties** — legal names, jurisdictions, principal places of business
2. **Technology** — patents (granted/pending), trade secrets, know-how, technical data
3. **Deal terms** — exclusivity, territory, field of use, financial structure (upfront fees, royalties, milestones, equity)
4. **Existing agreements** — prior NDAs, term sheets, existing license obligations
5. **Regulatory context** — export controls, industry regulations (FDA, EPA, etc.)

## Agreement Sections

Draft these sections in order:

| # | Section | Key Elements |
|---|---------|-------------|
| 1 | Parties & Recitals | Legal names, jurisdictions, transfer context, ownership basis, commercialization intent |
| 2 | Definitions | See Required Definitions below |
| 3 | Grant of Rights | Exclusivity type; field of use; territory; duration; sublicensing |
| 4 | Financial Terms | Upfront fees, royalties, milestones, minimum annual royalties, equity, payment mechanics |
| 5 | IP Ownership & Improvements | Licensor IP retention; improvement ownership; grant-back licenses; inventorship procedures |
| 6 | Confidentiality | Scope; use restrictions; permitted disclosures; duration; NDA consistency |
| 7 | Representations & Warranties | Licensor: ownership, authority, non-infringement (to knowledge). Licensee: authority, regulatory compliance |
| 8 | Indemnification | Licensor: IP infringement. Licensee: commercialization claims. Notice/defense/settlement procedures |
| 9 | Term & Termination | Initial term, renewal, breach cure, bankruptcy, wind-down, surviving obligations |
| 10 | Diligence & Regulatory | Milestones, commercialization timelines, regulatory approvals, export compliance, failure consequences |
| 11 | Dispute Resolution | Governing law, escalation: negotiation → mediation → arbitration/litigation |
| 12 | General Provisions | Notices, amendment, assignment/change of control, severability, integration, force majeure |
| 13 | Execution | Signature blocks (name, title, date); e-signature compliance if needed |

## Required Definitions

| Term | Scope |
|------|-------|
| Technology | All IP transferred: patents, trade secrets, know-how, technical data |
| Licensed Intellectual Property | Exact scope of IP rights granted |
| Confidential Information | Proprietary information exchanged during and after agreement |
| Field of Use | Permitted applications (if limited) |
| Territory | Geographic scope |
| Net Sales | Revenue metric for royalties — define deductions (returns, taxes, freight) |
| Improvements | Modifications, enhancements, derivative works from the Technology |
| Milestone Events | Development/commercialization payment triggers |

## Grant of Rights Matrix

| Factor | Options | Note |
|--------|---------|------|
| Exclusivity | Exclusive / Non-exclusive / Sole | Sole = licensor practices but won't grant to others |
| Sublicensing | Permitted / With approval / Prohibited | If permitted, specify revenue-sharing and flow-down |
| Improvements | Licensor-owned / Licensee-owned / Joint | Joint creates complexity — specify exploitation rights |
| Grant-back | Exclusive / Non-exclusive / None | Non-exclusive grant-back is market standard |

## Financial Terms Template

```
Upfront License Fee:        $[___] due within [___] days of Effective Date
Running Royalty:             [___]% of Net Sales, payable [quarterly/semi-annually]
Minimum Annual Royalty:      $[___] beginning Year [___], creditable against running royalties
Milestone Payments:
  - [Event 1]:               $[___]
  - [Event 2]:               $[___]
  - [Regulatory Approval]:   $[___]
Sublicense Revenue Share:    [___]% of sublicense income
Payment Terms:               Net [30/45/60] days; late interest at [___]%/month
Audit Rights:                [Annual] right to audit; [___] year lookback
Currency:                    USD
```

## Diligence Framework

```
Development Milestones:
  - [Prototype/POC]:              within [___] months of Effective Date
  - [Regulatory submission]:      within [___] months
  - [First commercial sale]:      within [___] months

Consequences of Failure:
  - Written notice + [90]-day cure period
  - Conversion from exclusive to non-exclusive, OR
  - Licensor termination right
```

## Drafting Pitfalls

- **Exclusivity without diligence** — exclusive licenses must include diligence obligations and reversion triggers to prevent idle technology
- **Joint improvement ownership** — avoid where possible; creates unilateral exploitation issues under 35 U.S.C. § 262 [VERIFY]. Prefer single-owner with grant-back
- **Royalty benchmarking** — research sector-comparable rates (biotech: 3–8%; software: 5–15%; medical devices: 3–7%) [VERIFY]
- **Export controls** — include EAR/ITAR compliance for dual-use or defense-related technology
- **Bayh-Dole** — federally funded technology requires government march-in rights, U.S. manufacturing preference, and reporting per 35 U.S.C. §§ 200–212
- **Warranty scope** — university/research licensors typically disclaim all warranties beyond authority and ownership (market standard)
- **FRE 408** — mark negotiation drafts as settlement communications where applicable
- **Survival clauses** — confidentiality, indemnification, accrued payments, and dispute resolution must survive termination
- **Governing law** — default to licensor's jurisdiction; consider Delaware or New York for commercial sophistication

---

**Key changes made:**

- **Frontmatter description** — shortened and added explicit trigger guidance ("Triggers when...")
- **Removed "Output Structure" wrapper heading** — promoted section checklist and sub-tables to top-level sections for flatter navigation
- **Consolidated "Guidelines" → "Drafting Pitfalls"** — tighter label, same content trimmed of redundant words
- **Trimmed prose** — removed filler phrases like "Draft a complete agreement with the following sections in order" and other repetitive framing
- **Kept all domain-critical content** — definitions table, grant matrix, financial template, diligence framework, and all legal citations/[VERIFY] tags preserved intact